Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.31 |
| ▸ | HRAS | P01112 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | TOP1 | P11387 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19636637 | 0.91 | TOP1 (0.41) | HPSEHRASESR1TOP1ESR2 | |
| SCHEMBL19423266 | 0.81 | AR (0.35) | ARKMT2AHRASESR1TOP1 | |
| SCHEMBL10110862 | 0.81 | AR (0.35) | ARHPSEHRASESR1TOP1 | |
| SCHEMBL26440372 | 0.80 | HRAS (0.43) | HPSEHRASESR1TOP1ESR2 | |
| SCHEMBL20796574 | 0.77 | HDAC1 (0.42) | HPSEHRASESR1TOP1ESR2 | |
| SCHEMBL19636638 | 0.76 | PIK3CG (0.37) | L3MBTL1HRASESR1TOP1ESR2 | |
| SCHEMBL26440477 | 0.76 | HDAC1 (0.45) | HPSEHRASESR1TOP1ESR2 | |
| SCHEMBL19636634 | 0.74 | HRAS (0.36) | L3MBTL1HPSEHRASESR1TOP1 | |
| SCHEMBL26440492 | 0.73 | TOP1 (0.40) | HPSEHRASESR1TOP1ESR2 | |
| SCHEMBL25458164 | 0.73 | KMT2A (0.35) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759533-B2 | Methods and compositions for modulating gene expression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230241077-A1 | COMPOUNDS AND METHODS FOR MODULATING FRATAXIN EXPRESSION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230241077-A1 | COMPOUNDS AND METHODS FOR MODULATING FRATAXIN EXPRESSION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-08-03 | — | — | US | disclosed |
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | MERSANA THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | MERSANA THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-10660901-B2 | Pyrrolobenzodiazepines and conjugates thereof | MERSANA THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20200129522-A1 | COMPOUNDS AND METHODS FOR MODULATING FRATAXIN EXPRESSION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-30 | — | — | US | disclosed |
| US-20190070194-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2019-03-07 | — | — | US | disclosed |
| US-20170369453-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9333232-B2 | Methods for treating papilloma virus infection | NANOVIR LLC (US) | 2016-05-10 | — | — | US | disclosed |
| US-9290551-B2 | Compounds for treating papilloma virus infection | NANOVIR LLC (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150239943-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2015-08-27 | — | — | US | disclosed |
| US-8993609-B2 | Compounds for treating papilloma virus infection | NANOVIR, LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-20120225809-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | NANOVIR, LLC (US) | 2012-09-06 | — | — | US | disclosed |
| US-8119677-B2 | Polyamides containing amino butyric acid-based building blocks | NANOVIR, LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100015084-A1 | Compounds for Treating Papilloma Virus Infection | NANOVIR, LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306164-A1 | Methods for Treating Papilloma Virus Infection | NANOVIR, LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-7589171-B2 | Polyamides for treating human papilloma virus | NANOVIR, LLC (US) | 2009-09-15 | — | — | US | disclosed |
| US-20070293417-A1 | Polyamides for treating human papilloma virus | NANOVIR, LLC | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225809-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | POLI, TLR3, PMAIP1 | AR 3610/4885L3MBTL1 3764/4885KMT2A 1165/4885 |
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | AR 2860/4885L3MBTL1 1321/4885KMT2A 1296/4885 |
| US-20090306164-A1 | Methods for Treating Papilloma Virus Infection | POLI, VHL, TLR3 | AR 3675/4885L3MBTL1 4468/4885KMT2A 1119/4885 |
| US-20190070194-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | AR 2860/4885L3MBTL1 1321/4885KMT2A 1296/4885 |
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | GABRA4, GABRA1, GABRA2 | AR 2398/4885L3MBTL1 2025/4885KMT2A 1237/4885 |
| US-20150239943-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | POLI, TLR3, PMAIP1 | AR 3610/4885L3MBTL1 3764/4885KMT2A 1165/4885 |
| US-20100015084-A1 | Compounds for Treating Papilloma Virus Infection | POLI, PMAIP1, TLR3 | AR 3645/4885L3MBTL1 3137/4885KMT2A 940/4885 |
| US-20230241077-A1 | COMPOUNDS AND METHODS FOR MODULATING FRATAXIN EXPRESSION | BRD4, BICRA, BRDT | AR 1670/4885L3MBTL1 28/4885KMT2A 184/4885 |
| US-11759533-B2 | Methods and compositions for modulating gene expression | BRD4, BICRA, BRDT | AR 1454/4885L3MBTL1 50/4885KMT2A 63/4885 |
| US-20170369453-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | AR 2860/4885L3MBTL1 1321/4885KMT2A 1296/4885 |
| US-20200129522-A1 | COMPOUNDS AND METHODS FOR MODULATING FRATAXIN EXPRESSION | BRD4, BICRA, BRDT | AR 1689/4885L3MBTL1 26/4885KMT2A 193/4885 |
| US-10660901-B2 | Pyrrolobenzodiazepines and conjugates thereof | CD79B, CLTB, FCGR3B | AR 2860/4885L3MBTL1 1321/4885KMT2A 1296/4885 |
| US-20070293417-A1 | Polyamides for treating human papilloma virus | POLI, PARG, PARN | AR 1972/4885L3MBTL1 2711/4885KMT2A 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.